The role of adjuvant hormonal therapy and optimized regimens for high-risk localized prostate cancer after radical prostatectomy remains controversial. Herein, the clinical trial CU 1005 prospectively evaluated two re...The role of adjuvant hormonal therapy and optimized regimens for high-risk localized prostate cancer after radical prostatectomy remains controversial. Herein, the clinical trial CU 1005 prospectively evaluated two regimens of maximum androgen blockage or bicalutamide 150 mg daily as immediate adjuvant therapy for high-risk localized prostate cancer. Overall, 209 consecutive patients were recruited in this study, 107 of whom received 9 months of adjuvant maximum androgen blockage, whereas 102 received 9 months of adjuvant bicalutamide 150 mg. The median postoperative follow-up time was 27.0 months. The primary endpoint was biochemical recurrence. Of the 209 patients, 59 patients developed biochemical recurrence. There was no difference between the two groups with respect to clinical characteristics, including age, pretreatment prostate-specific antigen, Gleason score, surgical margin status, or pathological stages. The maximum androgen blockage group experienced longer biochemical recurrence-free survival （P = 0.004） compared with the bicalutamide 150 mg group. Side-effects in the two groups were similar and could be moderately tolerated in all patients. In conclusion, immediate, 9-month maximum androgen blockage should be considered as an alternative to bicalutamide 150 mg as adjuvant treatment for high-risk localized prostate cancer patients after radical prostatectomy.展开更多
Pestaloamides A and B(1 and 2),two novel alkaloids featuring an unprecedented spiro[imidazothiazoledione-alkylidenecyclopentenone]scaffold,were obtained from the cultures of an endophytic fungus Pestalotiopsis sp.HS30...Pestaloamides A and B(1 and 2),two novel alkaloids featuring an unprecedented spiro[imidazothiazoledione-alkylidenecyclopentenone]scaffold,were obtained from the cultures of an endophytic fungus Pestalotiopsis sp.HS30 which inhabited the stems of Isodon xerophilus.Their planar structures and absolute configurations were fully determined by extensive spectroscopic analysis and X-ray crystallography.In addition,both compounds 1 and 2 showed the latent tumor immunotherapy activity through markedly promoting the cell surface engagement of NKG2 D ligands involving MICA/B and ULBP1 in HCT116 cells.展开更多
文摘The role of adjuvant hormonal therapy and optimized regimens for high-risk localized prostate cancer after radical prostatectomy remains controversial. Herein, the clinical trial CU 1005 prospectively evaluated two regimens of maximum androgen blockage or bicalutamide 150 mg daily as immediate adjuvant therapy for high-risk localized prostate cancer. Overall, 209 consecutive patients were recruited in this study, 107 of whom received 9 months of adjuvant maximum androgen blockage, whereas 102 received 9 months of adjuvant bicalutamide 150 mg. The median postoperative follow-up time was 27.0 months. The primary endpoint was biochemical recurrence. Of the 209 patients, 59 patients developed biochemical recurrence. There was no difference between the two groups with respect to clinical characteristics, including age, pretreatment prostate-specific antigen, Gleason score, surgical margin status, or pathological stages. The maximum androgen blockage group experienced longer biochemical recurrence-free survival （P = 0.004） compared with the bicalutamide 150 mg group. Side-effects in the two groups were similar and could be moderately tolerated in all patients. In conclusion, immediate, 9-month maximum androgen blockage should be considered as an alternative to bicalutamide 150 mg as adjuvant treatment for high-risk localized prostate cancer patients after radical prostatectomy.
基金the Second Tibetan Plateau Scientific Expedition and Research(STEP)Program(2019QZKK0502)the National Natural Science Foundation of China(81874298)+1 种基金the CAS“Light of West China”Program(Pema-Tenzin Puno)the Yunnan Science Fund for Distinguished Young Scholars(2019FJ002)。
文摘Pestaloamides A and B(1 and 2),two novel alkaloids featuring an unprecedented spiro[imidazothiazoledione-alkylidenecyclopentenone]scaffold,were obtained from the cultures of an endophytic fungus Pestalotiopsis sp.HS30 which inhabited the stems of Isodon xerophilus.Their planar structures and absolute configurations were fully determined by extensive spectroscopic analysis and X-ray crystallography.In addition,both compounds 1 and 2 showed the latent tumor immunotherapy activity through markedly promoting the cell surface engagement of NKG2 D ligands involving MICA/B and ULBP1 in HCT116 cells.
